Movement Alert｜AKESO Falls 3.03% in Regular Trading, positive ESMO biliary tract cancer data failed to offset post-placement pressure

Market Focus10-27

On October 27, AKESO fell 3.03% in Regular Trading, trading at HK$81.85, with turnover of HK$182 million.

The main recent catalyst in public information is that the company disclosed positive Phase III HARMONi-GI1 results for ivonescimab plus chemotherapy in first-line advanced biliary tract cancer, with the study selected for an ESMO Presidential Symposium oral presentation. The randomized, controlled, double-blind registrational trial enrolled 682 patients, and the indication had previously been proposed for priority review.

However, the stock has remained under pressure after the company completed a placement of 20 million new shares at HK$97.76 each, raising net proceeds of about HK$1.941 billion. The new shares represented about 2.13% of enlarged share capital, and the dilution and financing overhang appear to have limited the market reaction to the clinical update.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment